Sexual health often overlooked in cancer survivorship care, especially for female patients

October 30, 2020

ARLINGTON, Va., October 27, 2020 -- A new study points to a need for oncologists to ask their patients about sexual health after chemotherapy, radiation and other cancer treatments. In a survey of nearly 400 cancer survivors, 87% said they experienced sexual side effects, but most also said their oncologist had not formally asked about them. Female patients were especially unlikely to be asked about sexual dysfunction. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

"Sexual dysfunction is an unfortunately common side effect of cancer treatment, and there appears to be a large gender disparity in how physicians discuss sexual health with their patients," said lead author James Taylor, MD, MPH, chief resident in radiation oncology at the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia. "Our results show that we are asking men about sexual dysfunction caused by cancer treatment, but we are not asking women as frequently. We should be asking everyone, to determine how we can help."

Survivorship care is a growing focus in oncology as outcomes improve and patients live longer after treatment. Side effects that impact sexual function or desire are closely linked with quality of life. Potential issues for cancer survivors include physical complications such as erectile dysfunction with prostate cancer treatment or vaginal dryness with gynecological cancer treatment. Other issues include emotional and mental challenges such as body dysmorphia after mastectomy or decreased sexual desire with hormone therapy.

For this study, more than 400 adults completed an electronic survey about their experiences with sexual side effects after cancer treatment (391 responses were eligible for analysis). Most respondents were female (81%), and the most common cancer types were breast (67%), prostate (16%) and endometrial (6%) cancers. Treatments included chemotherapy (78%), radiation therapy (54%) and hormone therapy (47%).

Nearly nine in 10 respondents (87%) reported some change after treatment that negatively impacted their sexual health and quality of life. The most common side effects included painful intercourse (73%), body image distortion (54%) and inability to achieve orgasm (42%). Fewer than half of respondents (44%) said they were counseled preemptively that their sexual health could be affected by their cancer treatment.

Female cancer survivors were less likely to have their sexual side effects addressed than male survivors were. Male respondents were twice as likely to say they were asked and counseled about potential toxicity (53% vs. 22%, p<0.001) and substantially more male patients said they received a formal assessment tool such as a survey (32% vs. 5%, p=0.001).

"We were surprised at how infrequently sexual health and potential side effects of cancer treatment are discussed with female patients, especially compared to male patients," said Dr. Taylor.

Researchers also examined ways to foster these conversations and improve the patient experience. A majority of respondents (51%) said they would be most comfortable if the discussion about sexual health was initiated by their provider and guided by a standard questionnaire on possible side effects.

"Patients seem to prefer completing a survey or questions about their sexual health in clinic and then reviewing this information with their provider, rather than the physician directly asking the patient or the patient driving the discussion," explained Dr. Taylor. "A questionnaire administered to all patients can reduce uncomfortable feelings and make bridging the discussion much easier. We know that validated instruments exist, and it is time to put them into practice."

Because participants largely self-selected into the survey via social media, Dr. Taylor acknowledged that response bias may have influenced the high rates of sexual side effects. Next steps for the researchers include collecting additional responses to validate their findings and to include a broader variety of cancer types, as well as combining these results with a companion survey of oncologists that asks similar questions on sexual health discussions from the provider perspective. They also plan to conduct pilot studies that implement existing questionnaires in the clinic to identify where additional tools are needed.
-end-
 

ABOUT ASTRO


The American Society for Radiation Oncology (ASTRO) is the world's largest radiation oncology society , with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology * Biology * Physics, Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, RT Answers; and created the nonprofit foundation Radiation Oncology Institute. To learn more about ASTRO, visit our website and follow us on our blog, Facebook, Twitter and LinkedIn.

American Society for Radiation Oncology

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.